ABVC BIOPHARMA, INC. entered into Securities Purchase Agreement with Lind Global Fund II, LP valued at $3,704,167 (effective 2023-02-23).
“On February 23, 2023, ABVC BioPharma, Inc. (the “Company”) entered into a securities purchase agreement (the “Securities Purchase Agreement”) with Lind Global Fund II, LP (“Lind”), pursuant to which the Company would issue Lind a secured, convertible note in the principal amount of $3,704,167 (the “Offering”), for a purchase price of $3,175,000 (the “Note”), that is convertible into shares of the Company’s common stock at an initial conversion price of $1.05 per share, subject to adjustment (the “Note Shares”).”
Listing & Compliance Notices
ABVC BIOPHARMA, INC. received a nasdaq noncompliance notice notice regarding minimum bid price (rules 5550(a)(2)).
“August 19, 2022, ABVC BioPharma, Inc. (the “ Company ”) filed a Current Report on Form 8-K to report that it received a deficiency letter from the Nasdaq Listing Qualifications Department (the “ Staff ”) of the Nasdaq Stock Market LLC (“ Nasdaq ”) notifying the Company that, for the last 30 consecutive business days, the closing bid price for the Company’s common stock was below the minimum $1.00 per share required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (“ Rule 5550(a)(2) ”). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Compan”
Leeds Chow was appointed as Chief Financial Officer and Principal Accounting Officer at ABVC BIOPHARMA, INC..
“the Board has determined that it is in the best interests of ABVC BIOPHARMA, INC. (the “ Company ”) to reappoint Leeds Chow, age 34, the Company’s Controller, as Chief Financial Officer and Principal Accounting Officer.”
Yu-Min (Francis) Chung was appointed as Director at ABVC BIOPHARMA, INC..
“On July 10, 2022, the board of directors (“Board”) of the Company appointed Mr. Yu-Min (Francis) Chung as a director to fill the vacancy resulting from Mr. Chen’s resignation.”
Kuang-Tseng Chen resigned as Director at ABVC BIOPHARMA, INC..
“On July 10, 2022, Mr. Kuang-Tseng Chen, a director ABVC BioPharma, Inc. (the “Company”) notified the Company of his resignation from the board of directors for personal reasons, effective immediately.”
Hsin-Hui Miao was appointed as Director at ABVC BIOPHARMA, INC..
“the board appointed Ms. Hsin-Hui Miao to fill the vacancy created by Dr. Miao’s passing.”
Shin-Yu Miao departed as Director at ABVC BIOPHARMA, INC..
“On May 27, 2022, we were informed that one of our Directors, Dr. Shin-Yu Miao, passed away.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.